Skip to content
MTRIInMed Pharmaceuticals Inc.

Earnings

When InMed Pharmaceuticals Inc. reports, what it reported each quarter, and how the stock took the results.

29 quarters. Sep 30, 2019 to Sep 30, 2026. USD.

Next results · Q2 2027Projected

10-Q due Feb 2 – 16

No earnings release is on file for this company, so the day is the 10-Q’s, projected from its last 8 filings.

Quarter
Q2 2027 · Ends about Dec 31, 2026
10-Q window
Feb 2 – 16

Read against Q2 2026

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$820.19K
Revenue, change from a year earlier: Q2 2026 −26.2%, Q1 2026 −11.4%, Q4 2025 +1.7%, Q3 2025 +7.6%
Net income
-$2.03M
Net income, change from a year earlier: Q1 2027 n/m, Q4 2026 n/m, Q3 2026 n/m, Q2 2026 n/m
EPS
-$0.51
EPS, change from a year earlier: Q1 2027 n/m, Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m

Quarter by quarter

Q2 2026$820.19K−26.2% vs Q2 2025

Latest results

  1. Q1 2027Nov 2, 2026, after the close
    Revenue
    —
    —
    Net income
    -$2.33M
    N/M
    EPS
    -$0.42
    N/M
  2. Q4 2026Sep 9, 2026, after the close
    Revenue
    —
    —
    Net income
    -$5.84M
    N/M
    EPS
    —
    —
  3. Q3 2026May 6, 2026, after the close
    Revenue
    —
    —
    Net income
    -$2.97M
    N/M
    EPS
    -$0.73
    N/M
  4. Q2 2026Feb 11, 2026, after the close
    Revenue
    $820.19K
    −26.2%
    Net income
    -$2.03M
    N/M
    EPS
    -$0.51
    N/M

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2027
Q1 2027Sep 30, 2026—Nov 3, 202634 d10-Q——-$0.42—
FY 2026
Q4 2026derivedJun 30, 2026—Sep 9, 202671 d10-K————
Q3 2026Mar 31, 2026—May 6, 202636 d10-Q——-$0.73—
Q2 2026Dec 31, 2025—Feb 11, 202642 d10-Q$820.19K−26.2%-$0.51—
Q1 2026Sep 30, 2025—Nov 6, 202537 d10-Q$1.12M−11.4%-$0.44—
FY 2025
Q4 2025derivedJun 30, 2025—Sep 23, 202585 d10-K$1.30M+1.7%——
Q3 2025Mar 31, 2025—May 12, 202542 d10-Q$1.26M+7.6%-$1.94—
Q2 2025Dec 31, 2024—Feb 12, 202543 d10-Q$1.11M−10.4%-$3.64—
Q1 2025Sep 30, 2024—Nov 14, 202445 d10-Q$1.26M+40.2%-$2.71—
Earlier years, FY 2020 to FY 2024

Source filings

10-QNov 3, 2026115083
10-KSep 9, 2026098419
10-QMay 6, 2026052920
10-QFeb 11, 2026014996
10-QNov 6, 2025107152
10-KSep 23, 2025090210
10-QMay 12, 2025042126
10-QFeb 12, 2025013063
10-QNov 14, 2024098445
10-KSep 30, 2024082843

Provenance

ProvenanceData status and checks

InMed Pharmaceuticals Inc. · CIK 1728328 · Engraved from SEC EDGAR